Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment

Authors: Franca Marino, Andrea Maria Maresca, Marco Cosentino, Luana Castiglioni, Emanuela Rasini, Christian Mongiardi, Ramona C Maio, Massimiliano Legnaro, Laura Schembri, Francesco Dentali, Anna Maria Grandi, Luigina Guasti

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

In diabetes, a variety of pro-inflammatory cellular changes has been found in various cell types, including monocytes which are known to be involved in all the phases of atherogenesis. Angiotensin II (Ang II) type 1 receptor (AT1R) mediates the pro-atherogenic effects of Ang II whereas the type 2 receptor (AT2R) seems associated with atheroprotection. We sought to investigate the potential changes of AT1R-AT2R expression in human monocytes of type 2 diabetic- hypercholesterolemic patients and in hypercholesterolemic subjects, upon clinical treatment with rosuvastatin.

Methods

The AT1R membrane protein and mRNA AT1R and AT2R expression in monocytes were investigated in 10 type 2 diabetic-hypercholesterolemic patients and in 10 hypercholesterolemic subjects, before and after 3-month rosuvastatin treatment. Moreover, the serum cytokine levels of interferon-γ (IFN-γ) and interleukin-4 (IL-4) were detected.

Results

As expected, rosuvastatin was associated with a change in the lipid profile in the two groups. Both the membrane protein (P = 0.008) and the AT1R mRNA expression (P = 0.038) were significantly reduced during treatment in the absence of AT2R expression change in diabetic-hypercholesterolemic patients whereas no significant difference was observed in hypercholesterolemic subjects. The serum IL-4 levels were increased during treatment whereas no change was observed in IFN-γ in diabetic-hypercholesterolemic patients. No cytokine change was observed in hypercholesterolemic subjects.

Conclusions

Our study on monocytes of diabetic-hypercholesterolemic patients, showing a reduced AT1R but not AT2R expression during rosuvastatin treatment, suggests that statin therapy may modulate favorably the AT1-AT2 receptor balance in subjects with coexistent type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007, 49: 2129-2138. 10.1016/j.jacc.2007.02.052.CrossRefPubMed
2.
Tedgui A, Mallat Z: Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways. Physiol Rev. 2006, 86: 515-581. 10.1152/physrev.00024.2005.CrossRefPubMed
3.
Mogi M, Iwai M, Horiuchi M: Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol. 2007, 27: 2532-2539. 10.1161/ATVBAHA.107.144154.CrossRefPubMed
4.
Petnehazy T, Stokes KY, Wood KC, Russell J, Granger DN: Role of Blood Cell–Associated AT1 Receptors in the Microvascular Responses to Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006, 26: 313-318.CrossRefPubMed
5.
Tone A, Shikata K, Ogawa D, Sasaki S, Nagase R, Sasaki M, Yozai K, Usui HK, Okada S, Wada J, Shikata Y, Makino H: hanges of gene expression profiles in macrophages stimulated by angiotensin II-angiotensin II induces MCP-2 through AT1-receptor. J Renin Angiotensin Aldosterone Syst. 2007, 8: 45-50. 10.3317/jraas.2007.007.CrossRefPubMed
6.
Savoia C, Touyz RM, Volpe M, Schiffrin EL: Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. Hypertension. 2007, 49: 341-346.CrossRefPubMed
7.
Hernandez Schulman I, Zhou MS, Raij L: Cross-Talk Between Angiotensin II Receptor Types 1 and 2. Hypertension. 2007, 49 (Hernandez Schulman I, Zhou MS, Raij L): 270-271.CrossRefPubMed
8.
Carey RM: Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor. The AT2 Receptor Comes of Age. Hypertension. 2005, 45: 840-844. 10.1161/01.HYP.0000159192.93968.8f.CrossRefPubMed
9.
Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371: 117-125. 10.1016/S0140-6736(08)60104-X.CrossRef
10.
Arora M, Chen L, Paglia M, Gallagher I, Allen JE, Vyas YM, Ray A, Ray P: Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci USA. 2006, 103: 7777-7782. 10.1073/pnas.0508492103.PubMedCentralCrossRefPubMed
11.
Westerink J, Visseren FLJ: Pharmacological and non pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol. 2011, 10: 13-10.1186/1475-2840-10-13.PubMedCentralCrossRefPubMed
12.
Marino F, Guasti L, Cosentino M, Ferrari M, Rasini E, Maio RC, Cimpanelli MG, Cereda E, Crespi C, Simoni C, Restelli D, Venco A, Lecchini S: Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007, 49: 299-305. 10.1097/FJC.0b013e31803d35ce.CrossRefPubMed
13.
14.
Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, Jandeleit-Dahm KA: The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol. 2010, 299: F528-F535. 10.1152/ajprenal.00127.2010.CrossRefPubMed
15.
Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G: Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. 2010, 299: F1203-F1211. 10.1152/ajprenal.00045.2010.CrossRefPubMed
16.
Zadelaar S, Kleemann R, Verschuren L, De Vries-Van Der Weij J, Van der Hoorn J, Princen HM, Kooistra T: Mouse Models for Atherosclerosis and Pharmaceutical Modifiers. Arterioscler Thromb Vasc Biol. 2007, 27: 1706-1721. 10.1161/ATVBAHA.107.142570.CrossRefPubMed
17.
Marino F, Guasti L, Cosentino M, Rasini E, Ferrari M, Maio RC, Loraschi A, Cimpanelli MG, Schembri L, Legnaro M, Molteni E, Crespi C, Crema F, Venco A, Lecchini S: Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008, 26: 1147-1155. 10.1097/HJH.0b013e3282f97dde.CrossRefPubMed
18.
Guasti L, Marino F, Cosentino M, Cimpanelli M, Maio RC, Klersy C, Crespi C, Restelli D, Simoni C, Franzetti I, Gaudio G, Marnini P, Grandi AM, Lecchini S, Venco A: Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. J Hypertens. 2006, 24: 2423-2430. 10.1097/01.hjh.0000251903.62804.77.CrossRefPubMed
19.
Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, Castiglioni L, Klersy C, Gaudio G, Grandi AM, Lecchini S, Venco A: Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J. 2008, 29 (9): 1118-1126. 10.1093/eurheartj/ehn138.CrossRefPubMed
20.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: For the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. N Engl J Med. 1994, 330: 877-884. 10.1056/NEJM199403313301301.CrossRefPubMed
21.
Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, Venco A, Lecchini S: Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept. 2006, 134: 69-74. 10.1016/j.regpep.2006.01.007.CrossRefPubMed
22.
Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006, 47: 1093-1100. 10.1016/j.jacc.2005.11.046.CrossRefPubMed
23.
Lafuente N, Matesanz N, Azcutia V, Romacho T, Nevado J, Rodríguez-Mañas L, Moncada S, Peiró C, Sánchez-Ferrer CF: The deleterious effect of high concentrations of D-glucose requires pro-inflammatory preconditioning. J Hypertens. 2008, 26: 478-485. 10.1097/HJH.0b013e3282f331fb.CrossRefPubMed
24.
Liang CP, Han S, Senokuchi T, Tall AR: The Macrophage at the Crossroads of Insulin Resistance and Atherosclerosis. Circ Res. 2007, 100: 1546-1555. 10.1161/CIRCRESAHA.107.152165.CrossRefPubMed
25.
Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K: Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiol. 2007, 43: 455-464. 10.1016/j.yjmcc.2007.07.044.CrossRefPubMed
26.
Reuter H, Adam C, Grönke S, Zobel C, Frank KF, Müller-Ehmsen J, Brabender J, Schwinger RH: The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system. Diabetologia. 2006, 49: 3067-3074. 10.1007/s00125-006-0444-8.CrossRefPubMed
27.
Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon MC, Feugier P, Beylot M, Randon J, Bricca G: Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol. 2007, 27: 525-531. 10.1161/01.ATV.0000254814.63768.3b.CrossRefPubMed
28.
Carey RM: Angiotensin Receptors and Aging. Hypertension. 2007, 50: 33-34. 10.1161/HYPERTENSIONAHA.106.086587.CrossRefPubMed
29.
Van de Wal RM, van der Harst P, Wagenaar LJ, Wassmann S, Morshuis WJ, Nickenig G, Buikema H, Plokker HW, van Veldhuisen DJ, van Gilst WH, Voors AA: Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. J Cardiovasc Pharmacol. 2007, 50: 372-379. 10.1097/FJC.0b013e31811ea222.CrossRefPubMed
30.
Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH: Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004, 109: 2296-2301. 10.1161/01.CIR.0000128696.12245.57.CrossRefPubMed
31.
Link A, Ayadhi T, Böhm M, Nickenig G: Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J. 2006, 27: 2945-2955. 10.1093/eurheartj/ehl277.CrossRefPubMed
32.
Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic. Arterioscler Thromb Vasc Biol. 2002, 22: 1194-1199. 10.1161/01.ATV.0000022694.16328.CC.CrossRefPubMed
33.
Devaraj S, Chan E, Jialal I: Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006, 91: 4489-4496. 10.1210/jc.2006-0299.CrossRefPubMed
34.
Coward W, Chow SC: Effect of atorvastatin on Th1 and Th2 cytokine secreting cells during T cell activation and differentiation. Atherosclerosis. 2006, 186: 302-309. 10.1016/j.atherosclerosis.2005.08.013.CrossRefPubMed
Metadata
Title
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment
Authors
Franca Marino
Andrea Maria Maresca
Marco Cosentino
Luana Castiglioni
Emanuela Rasini
Christian Mongiardi
Ramona C Maio
Massimiliano Legnaro
Laura Schembri
Francesco Dentali
Anna Maria Grandi
Luigina Guasti
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-153

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue

Original investigation

Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution

Original investigation

Lp(a)-cholesterol is associated with HDL-cholesterol in overweight and obese African American children and is not an independent risk factor for CVD

Original investigation

The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice

Original investigation

Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey

Original investigation

High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study

Original investigation

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits